Cardiology biotech Kardigan prices its Nasdaq IPO at $16, the top of range, raising $400M ahead of a Thursday debut.
Kardigan CEO Tassos Gianakakos
June 17, 2026 08:48 PM EDT
IPOs
Kardigan raises $400M in IPO to back three clinical-stage cardio drugs
Kyle LaHucik
Kardigan raises $400M in upsized US IPO, pricing at top of range
Kardigan extends biotech’s streak of big IPOs with $400M haul
Kardigan Announces Pricing of Upsized Initial Public Offering
Kardigan Announces Closing of Initial Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares
How Kardigan spun deal leftovers into a $400M IPO
Carlyle eyes $1 billion raise via auto, healthcare IPOs
Kardigan raised $400 million in its upsized Nasdaq IPO, pricing at $16 per share at the top of its range, signaling renewed…
Kardigan launches $320M IPO to fund three late-stage cardio drugs as biotech listings hit a post-pandemic high.
Cardiology biotech Kardigan filed for a Nasdaq IPO under ticker {$KARD}, joining a growing roster of clinical-stage drug…
Kardigan plans to use the IPO funds to push its three in-licensed, mid-to-late-stage heart health therapies down the clinical…
Including the heart drug developer’s offering, four biotechs in 2026 have raised at least $400 million in IPO proceeds — the most…
Kardigan Announces Pricing of Upsized Initial Public Offering
